These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36187072)

  • 41. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
    van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib protects against human beta-cell death via inhibition of mitochondrial respiration and activation of AMPK.
    Elksnis A; Schiffer TA; Palm F; Wang Y; Cen J; Turpaev K; Ngamjariyawat A; Younis S; Huang S; Shen Y; Leng Y; Bergsten P; Karlsborn T; Welsh N; Wang X
    Clin Sci (Lond); 2021 Oct; 135(19):2243-2263. PubMed ID: 34569605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
    Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
    Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
    Dziba JM; Ain KB
    J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
    Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. STI571 (imatinib mesylate): the tale of a targeted therapy.
    Thambi P; Sausville EA
    Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effect of tyrosine kinase inhibitor imatinib mesylate on K562 cell invasion by PTEN pathway].
    Cheng ZY; Liang WT; Yan XY; Wan JS; Bian YS; Bai P; Liang LQ; Jie JQ; Li AM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1129-32. PubMed ID: 23127398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
    Maekawa T; Ashihara E; Kimura S
    Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imatinib mesylate.
    Waller CF
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
    Holtz MS; Slovak ML; Zhang F; Sawyers CL; Forman SJ; Bhatia R
    Blood; 2002 May; 99(10):3792-800. PubMed ID: 11986238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro.
    Mokhtari D; Li T; Lu T; Welsh N
    PLoS One; 2011; 6(9):e24831. PubMed ID: 21935477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells.
    Xu Y; Fang F; Sun Y; St Clair DK; St Clair WH
    Mol Cancer Ther; 2010 Apr; 9(4):803-12. PubMed ID: 20371728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
    Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
    Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
    Zoubir M; Tursz T; Ménard C; Zitvogel L; Chaput N
    Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):1-7. PubMed ID: 19839938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.